alendronate has been researched along with Hypophosphatasia in 2 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Hypophosphatasia: A genetic metabolic disorder resulting from serum and bone alkaline phosphatase deficiency leading to hypercalcemia, ethanolamine phosphatemia, and ethanolamine phosphaturia. Clinical manifestations include severe skeletal defects resembling vitamin D-resistant rickets, failure of the calvarium to calcify, dyspnea, cyanosis, vomiting, constipation, renal calcinosis, failure to thrive, disorders of movement, beading of the costochondral junction, and rachitic bone changes. (From Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a 55-year-old woman who suffered atypical subtrochanteric femoral fractures (ASFFs) after 4 years of exposure to alendronate and then zolendronate given for "osteoporosis." | 3.78 | "Atypical femoral fractures" during bisphosphonate exposure in adult hypophosphatasia. ( Coburn, SP; Ericson, KL; Mumm, S; Sutton, RA; Whyte, MP, 2012) |
| "Alendronate treatment was discontinued and, while a suitable kidney donor was sought, the patient was treated for 6 months with teriparatide, which significantly reduced the osteomalacia." | 1.42 | Reversible Deterioration in Hypophosphatasia Caused by Renal Failure With Bisphosphonate Treatment. ( Collins, JF; Cundy, T; Dray, M; Fratzl-Zelman, N; Gamsjaeger, S; Klaushofer, K; Michigami, T; Paschalis, EP; Roschger, A; Roschger, P; Tachikawa, K, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cundy, T | 1 |
| Michigami, T | 1 |
| Tachikawa, K | 1 |
| Dray, M | 1 |
| Collins, JF | 1 |
| Paschalis, EP | 1 |
| Gamsjaeger, S | 1 |
| Roschger, A | 1 |
| Fratzl-Zelman, N | 1 |
| Roschger, P | 1 |
| Klaushofer, K | 1 |
| Sutton, RA | 1 |
| Mumm, S | 1 |
| Coburn, SP | 1 |
| Ericson, KL | 1 |
| Whyte, MP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Whole Exome Sequencing to Identify Genetic Predisposition to Atypical Femoral Fractures in Women Using Bisphosphonates for Osteoporosis[NCT02731040] | 38 participants (Actual) | Observational | 2016-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for alendronate and Hypophosphatasia
| Article | Year |
|---|---|
Reversible Deterioration in Hypophosphatasia Caused by Renal Failure With Bisphosphonate Treatment.
Topics: Alendronate; Densitometry; Diphosphonates; DNA Mutational Analysis; Fractures, Bone; Genetic Associa | 2015 |
"Atypical femoral fractures" during bisphosphonate exposure in adult hypophosphatasia.
Topics: Alendronate; Diphosphonates; Female; Femoral Fractures; Humans; Hypophosphatasia; Imidazoles; Middle | 2012 |